Pipeline

Advancing a novel product candidate for cardiometabolic disorders

Prioritizing the development of ninerafaxstat in high value cardiometabolic indications.

We have initiated the Phase 2b FORTITUDE-HCM clinical trial.

Phase 2a clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and cardiometabolic heart failure with preserved ejection fraction (HFpEF). 

ninerafaxstat

For the Treatment of Cardiometabolic Disorders

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

URL: